Evrópusambandið - íslenska - EMA (European Medicines Agency)

lipomed gmbh - dauða - mergæxli - Ónæmisbælandi lyf - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

aspen pharma trading limited - melphalanum inn - filmuhúðuð tafla - 2 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,125 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,25 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,5 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn - innöndunarduft - 100 míkróg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn - innöndunarduft - 200 míkróg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn - innöndunarduft - 400 míkróg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/0,02 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - ethinylestradiolum inn; cyproteronum acetat - húðuð tafla - 2/0,035 mg